Manta Bidco, which now owns Mediclinic, expects 5% USD revenue growth and a 15% adjusted EBITDA margin for the year ended 31 March 2025 | Hirslanden in Switzerland anticipates 2% CHF revenue growth and a 13.5% adjusted EBITDA margin, with inpatient admissions up 2% | Mediclinic Southern Africa projects 7.5% ZAR revenue growth, an 18.2% adjusted EBITDA margin, with paid patient days rising 1% | Lastly, Mediclinic Middle East forecasts 5% revenue growth, a 15.0% adjusted EBITDA margin, with inpatient admissions up 4%.
Click here to read the SENS